3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, T-Cell, Peripheral
3
Myelodysplastic Syndromes
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Neuroendocrine Tumors
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Eye Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Neuroendocrine
1
Blast Crisis
1
Interventions
Magnetic Resonance Spectroscopy
10
trametinib
7
Nivolumab
7
selpercatinib
6
pembrolizumab
6
dabrafenib
6
Iodine-131
6
Specimen Handling
5
Biopsy
5
lenvatinib
4
Vemurafenib
4
Iodine-124
4
durvalumab
3
cabozantinib
3
binimetinib
3
Ipilimumab
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Cetuximab
3
vandetanib
2
ulixertinib
2
omipalisib
2
larotrectinib
2
defactinib
2
copanlisib
2
cemiplimab
2
anlotinib
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
belinostat
×
1 year
×
Clear all
No trials found.